文献速递胸部肿瘤

纳武利尤单抗联合伊匹木单抗加两周期化疗一线治疗非小细胞肺癌(CheckMate 9LA):国际随机开放标签3期试验

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-01-18

CheckMate 9LA研究纳入1150例初治IV期或复发NSCLC患者,随机接受纳武利尤单抗+伊匹木单抗联合2周期化疗或单纯4周期化疗。联合组3-4级治疗相关不良事件以中性粒细胞减少、贫血、腹泻、脂肪酶升高和乏力常见,严重不良事件发生率30% vs 18%。

要点

  • 纳武利尤单抗+伊匹木单抗+2周期化疗一线治疗晚期NSCLC显著改善OS。
  • 联合组严重治疗相关不良事件发生率30%,化疗组18%。

核心结论

  • 纳武利尤单抗联合伊匹木单抗加两周期化疗较单纯化疗显著改善晚期NSCLC患者的总生存,且风险获益良好,支持作为新的一线治疗选择。

研究设计与样本

  • 国际、随机、开放标签、3期试验,在19个国家103家医院进行。
  • 纳入1150例初治、组织学确诊的IV期或复发NSCLC患者,ECOG PS 0-1,随机1:1分配至联合组(n=361)或化疗组(n=358)。
  • 联合组方案:纳武利尤单抗360 mg IV每3周+伊匹木单抗1 mg/kg IV每6周+基于组织学的铂类双药化疗IV每3周共2周期;对照组:化疗每3周共4周期。
  • 主要终点为所有随机化患者的总生存;安全性分析纳入所有接受治疗患者。

主要发现

  • 最常见3-4级治疗相关不良事件:中性粒细胞减少(联合组7% vs 化疗组9%)、贫血(6% vs 14%)、腹泻(4% vs 1%)、脂肪酶升高(6% vs 1%)、乏力(1% vs 2%)。
  • 任何级别严重治疗相关不良事件发生率联合组30% vs 化疗组18%;治疗相关死亡联合组7例(2%),化疗组6例(2%)。

临床怎么用

  • 对于初治晚期NSCLC且ECOG PS 0-1的患者,可考虑纳武利尤单抗联合伊匹木单抗加两周期化疗作为一线治疗选择。
  • 治疗期间需监测免疫相关不良事件及化疗相关毒性,尤其是严重治疗相关不良事件的发生。

局限性

  • 开放标签设计可能影响不良事件报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit. METHODS: This randomised, open-label, phase 3 trial was done at 103 hospitals in 19 countries. Eligible patients were aged 18 years or older with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) by an interactive web response system via permuted blocks (block size of four) to nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles; experimental group), or chemotherapy alone (every 3 weeks for four cycles; control group). Randomisation was stratified by tumour histology, sex, and PD-L1 expression. The primary endpoint was overall survival in all randomly assigned patients. Safety was analysed in all treated patients. Results reported here are from a pre-planned interim analysis (when the study met its primary endpoint) and an exploratory longer-term follow-up analysis. This study is active but no longer recruiting patients, and is registered with ClinicalTrials.gov, number NCT03215706. FINDINGS: Between Aug 24, 2017, and Jan 30, 2019, 1150 patients were enrolled and 719 (62·5%) randomly assigned to nivolumab plus ipilimumab with two cycles of chemotherapy (n=361 [50%]) or four cycles of chemotherapy alone (n=358 [50%]). At the pre-planned interim analysis (median follow-up 9·7 months [IQR 6·4-12·8]), overall survival in all randomly assigned patients was significantly longer in the experimental group than in the control group (median 14·1 months [95% CI 13·2-16·2] vs 10·7 months [9·5-12·4]; hazard ratio [HR] 0·69 [96·71% CI 0·55-0·87]; p=0·00065). With 3·5 months longer median follow-up (median 13·2 months [IQR 6·4-17·0]), median overall survival was 15·6 months (95% CI 13·9-20·0) in the experimental group versus 10·9 months (9·5-12·6) in the control group (HR 0·66 [95% CI 0·55-0·80]). The most common grade 3-4 treatment-related adverse events were neutropenia (in 24 [7%] patients in the experimental group vs 32 [9%] in the control group), anaemia (21 [6%] vs 50 [14%]), diarrhoea (14 [4%] vs two [1%]), increased lipase (22 [6%] vs three [1%]), and asthenia (tjree [1%] vs eight [2%]). Serious treatment-related adverse events of any grade occurred in 106 (30%) patients in the experimental group and 62 (18%) in the control group. Seven (2%) deaths in the experimental group (acute kidney failure, diarrhoea, hepatotoxicity, hepatitis, pneumonitis, sepsis with acute renal insufficiency, and thrombocytopenia; one patient each) and six (2%) deaths in the control group (anaemia, febrile neutropenia, pancytopenia, pulmonary sepsis, respiratory failure, and sepsis; one patient each) were treatment related. INTERPRETATION: Nivolumab plus ipilimumab with two cycles of chemotherapy provided a significant improvement in overall survival versus chemotherapy alone and had a favourable risk-benefit profile. These data support this regimen as a new first-line treatment option for patients with advanced NSCLC. FUNDING: Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021. PMID: 33476593. doi:10.1016/S1470-2045(20)30641-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。